title: Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?
authors.forename: Ronit
authors.initials: R
authors.lastname: Yerushalmi
authors.forename: Itay
authors.initials: I
authors.lastname: Levi
authors.forename: Marc
authors.initials: M
authors.lastname: Wygoda
authors.forename: Gal
authors.initials: G
authors.lastname: Ifergane
authors.forename: Itzhak
authors.initials: I
authors.lastname: Wirguin
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018236:Carcinoma, Embryonal / Q000188:drug therapy; D002607:Charcot-Marie-Tooth Disease / Q000139:chemically induced* / Q000473:pathology; D002945:Cisplatin / Q000009:adverse effects*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013736:Testicular Neoplasms / Q000188:drug therapy; D014750:Vincristine / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D002945:Cisplatin